Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed MergerGlobeNewsWire • 09/04/24
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug DeveloperBenzinga • 07/22/24
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' TrialGlobeNewsWire • 04/19/24
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael PurcellGlobeNewsWire • 03/06/24
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsGlobeNewsWire • 02/16/24
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesGlobeNewsWire • 12/07/23
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitGlobeNewsWire • 11/28/23
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of RencofilstatGlobeNewsWire • 11/10/23
Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelGlobeNewsWire • 10/25/23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 09/29/23
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/21/23
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary FibrosisGlobeNewsWire • 09/14/23
Wall Street Analysts Think Hepion Pharmaceuticals, Inc. (HEPA) Could Surge 674.09%: Read This Before Placing a BetZacks Investment Research • 09/06/23
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023GlobeNewsWire • 06/15/23
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH' Trial of RencofilstatGlobeNewsWire • 06/15/23
Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical SciencesGlobeNewsWire • 05/24/23
Hepion Pharmaceuticals' Phase 2 ‘ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH BiomarkersGlobeNewsWire • 05/22/23